India Diabetes Drugs Market Analysis Report [2022-30]

India Diabetes Drugs Market Analysis

$ 3999

The India diabetes drugs market size was valued at $1.12 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.10% from 2022 to 2030 and will reach $2.25 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The India diabetes drug market will grow because India’s high prevalence of diabetes, the increasing demand for newer, more effective treatments, and the growing focus on prevention and early intervention. The key market players are Biocon (IND), Sun Pharma (IND), Lupin (IND), Cadila Healthcare (IND), Dr. Reddy's Laboratories (IND), and others.

ID: IN10INPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Chandani Patel

Buy Now

India Diabetes Drugs Market Executive Summary

The India diabetes drugs market size was valued at $1.12 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.10% from 2022 to 2030 and will reach $2.25 Bn in 2030. India's health expenditure has been increasing over the past few years, but it still lags behind many other countries in terms of per capita spending on healthcare. According to data from the World Health Organization (WHO), India's total health expenditure was around 3.6% of GDP in 2019. This is relatively low compared to other countries, such as the United States, which spends around 17% of its GDP on healthcare.

In terms of government spending on healthcare, India has also been increasing its budget allocation in recent years. The Union Budget 2021-22 announced a 137% increase in health and well-being spending, with a total allocation of $30 Bn. This includes funding for various health-related initiatives, such as the implementation of the Ayushman Bharat health insurance scheme, the establishment of new health institutions, and the expansion of primary healthcare services.

Diabetes is a significant health challenge in India, with an estimated 77 Mn adults living with the condition as of 2021, according to the International Diabetes Federation. This represents a prevalence rate of around 8.9%, which is one of the highest in the world. Diabetes is a major contributor to morbidity and mortality in India and is associated with a range of complications, including cardiovascular disease, kidney disease, and blindness.

The high prevalence of diabetes in India has significant implications for the diabetes drugs market in the country. The market for diabetes drugs in India is expected to grow rapidly in the coming years, driven by factors such as the increasing prevalence of the disease, the growing awareness of diabetes and its complications, and the improving access to healthcare and medical treatments. One of the key drivers of growth in the diabetes drugs market in India is the increasing demand for newer, more effective treatments. In recent years, there has been a shift towards the use of newer diabetes drugs, such as GLP-1 receptor agonists and SGLT-2 inhibitors, which have been shown to be effective in reducing blood glucose levels and preventing complications in people with diabetes.

Another factor contributing to the growth of the diabetes drug market in India is the increasing focus on prevention and early intervention. There is growing recognition of the importance of preventing and managing diabetes through lifestyle changes, such as healthy eating and exercise, as well as through the use of medications.

india diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

The diabetes drugs market in India is driven by several factors, including the high prevalence of diabetes, the increasing demand for newer, more effective treatments, and the growing focus on prevention and early intervention. The high prevalence of diabetes in India is a major driver of growth in the diabetes drugs market, with an estimated 77 Mn adults living with the condition as of 2021. This has created a significant market opportunity for pharmaceutical companies, who are working to develop and market new treatments that can help to address this major public health challenge. The increasing demand for newer, more effective treatments is also driving growth in the diabetes drug market in India. In recent years, there has been a shift towards the use of newer diabetes drugs, such as GLP-1 receptor agonists and SGLT-2 inhibitors, which have been shown to be effective in reducing blood glucose levels and preventing complications in people with diabetes.

Market Restraints

One of the major challenges is the affordability and accessibility of diabetes drugs, particularly for low-income populations. The high cost of newer diabetes drugs can be a barrier to access for many patients, and this is a particular concern in India, where a large proportion of the population lives below the poverty line. Another challenge facing the diabetes drugs market in India is the lack of awareness and education about diabetes and its management. Many people with diabetes in India may not be aware of the importance of monitoring their blood glucose levels or may not have access to the resources they need to manage their condition effectively.

Competitive Landscape

Key Players

Biocon (IND)
Sun Pharma (IND)
Lupin (IND)
Cadila Healthcare (IND)
Dr. Reddy's Laboratories (IND)
Sanofi
Johnson & Johnson
Abott
Bayer Pharmaceuticals
Novo Nordisk
Merck
Eli Lilly and Company
AstraZeneca
Boehringer Ingelheim
Novartis
GlaxoSmithKline

Notable deals

January 2021: Indian pharmaceutical company Lupin announced that it had entered into a licensing agreement with Boehringer Ingelheim for its diabetes drug linagliptin. Under the agreement, Lupin will have the exclusive rights to market and distribute linagliptin in India.

March 2021: Sun Pharma and AstraZeneca announced a partnership to distribute the diabetes drug dapagliflozin in India. Dapagliflozin is an SGLT-2 inhibitor that is used to treat type 2 diabetes.

July 2021: Biocon Biologics, a subsidiary of Indian biopharmaceutical company Biocon, announced that it had entered into a partnership with Brazil-based Libbs Farmaceutica to market and distribute insulin products in Brazil. The partnership will also explore opportunities to expand into other markets, including India.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

In India, diabetes drugs are regulated by the Central Drugs Standard Control Organization (CDSCO), which is responsible for ensuring the safety, efficacy, and quality of pharmaceuticals in the country. The CDSCO is part of the Ministry of Health and Family Welfare, and it regulates the approval and sale of diabetes drugs through a process of clinical trials and regulatory review.

In terms of reimbursement, the cost of diabetes drugs is partially covered by the government through its public health insurance scheme, Ayushman Bharat. Ayushman Bharat provides free or subsidized healthcare to low-income individuals and families, and it covers the cost of diabetes drugs for eligible patients. In addition to government reimbursement, many private insurance companies in India also cover the cost of diabetes drugs as part of their healthcare coverage. However, the coverage and reimbursement rates can vary significantly depending on the insurance plan, and many patients still face significant financial barriers to accessing the diabetes drugs they need.

There are also ongoing efforts to improve access to diabetes drugs in India through initiatives such as price controls and generic drug substitution. In 2013, the Indian government introduced a policy to cap the prices of essential medicines, including diabetes drugs, in an effort to make them more affordable and accessible to patients. This policy has helped to reduce the cost of diabetes drugs in India, but there are concerns that it may also limit innovation and investment in the diabetes drugs market.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.